Literature DB >> 15709048

The diagnosis and therapy of tuberculosis during the past 100 years.

Denis A Mitchison1.   

Abstract

Methods for the radiographic diagnosis of tuberculosis have improved from simple fluoroscopy to computerized tomography. Although direct smear examination is still the most widely used bacteriological method of diagnosis, cultural methods with selective liquid media are sensitive and rapid. The use of antituberculosis drugs has changed tuberculosis from a disease with about a 50% mortality, treated by measures to collapse the affected lung lesions and by rest for the patient, to a condition successfully curable by chemotherapy. Key steps in the development of modern chemotherapy regimens were the demonstrations in clinical trials that (1) streptomycin was effective; (2) combination of drugs prevented the emergence of drug-resistant Mycobacterium tuberculosis; (3) chemotherapy under domiciliary conditions was effective and did not put family members at risk of infection; (4) patient compliance could be assisted by fully supervised intermittent regimens, or more effectively, by (5) shortening treatment by the introduction of rifampin and pyrazinamide, the two most potent sterilizing drugs, into the regimens. Regimens were divided into an initial intensive phase, while bacterial populations were high, and a longer continuation phase to complete sterilization. Pyrazinamide was shown to sterilize only in the intensive phase. The treatment of nonpulmonary tuberculosis followed the same plan, but when bacterial populations are low, fewer drugs are required in combination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709048     DOI: 10.1164/rccm.200411-1603OE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 3.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

Review 4.  Novel classes of antibiotics or more of the same?

Authors:  Anthony R M Coates; Gerry Halls; Yanmin Hu
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

Authors:  Claudio U Köser; Sophia B Georghiou; Thomas Schön; Max Salfinger
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

6.  A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice.

Authors:  Ruchi Pandey; G Marcela Rodriguez
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

7.  The trehalose-specific transporter LpqY-SugABC is required for antimicrobial and anti-biofilm activity of trehalose analogues in Mycobacterium smegmatis.

Authors:  Jeffrey M Wolber; Bailey L Urbanek; Lisa M Meints; Brent F Piligian; Irene C Lopez-Casillas; Kailey M Zochowski; Peter J Woodruff; Benjamin M Swarts
Journal:  Carbohydr Res       Date:  2017-08-09       Impact factor: 2.104

Review 8.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

Review 9.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

10.  Medical management of genitourinary tuberculosis.

Authors:  Tamilarasu Kadhiravan; Surendra K Sharma
Journal:  Indian J Urol       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.